New Indication: Perioperative Durvalumab for NSCLC

A Phase III, double-blind, placebo-controlled, multicenter, international Study (AEGEAN)

Resectable Stages IIA to IIIB Non-small Cell Lung Cancer

Perioperative Durvalumab + Chemotherapy (n=366) vs. chemotherapy (n=374)

pCR: 17.2% vs. 4.2%

mPR: 33% vs. 13%

ORR: 56.3% vs. 38.0%

mEFS: NR vs. 25.9 mos, HR:0.68

12 mos EFS: 73.4 % vs. 64.5%

24 mos EFS: 63.3% vs. 52.4%

Grade3: Neutrophenia (9.7% vs. 10.8%), anemia (6.5 % vs. 6.5%)

Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023

durvalumab